Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Ready To Unveil "Council For Technology & Innovation"

This article was originally published in The Pink Sheet Daily

Executive Summary

The council will establish two working groups: the "Better Evidence" group will focus on improving clinical data available for coverage decisions and the "Effective Innovation" group will develop ways to improve the efficiency of the coverage decision process. CMS' Herbert Kuhn and Sean Tunis will co-chair the council.

You may also be interested in...



CMS Developing Guidance On Coverage Decisions For Clinical Trials

The guidance will address questions about CMS’ priority setting and methodologies for making coverage decisions in the future. The document will be one of the first produced under CMS’ new guidance development process, details of which will be released in the next two weeks.

CMS Developing Guidance On Coverage Decisions For Clinical Trials

The guidance will address questions about CMS’ priority setting and methodologies for making coverage decisions in the future. The document will be one of the first produced under CMS’ new guidance development process, details of which will be released in the next two weeks.

Medicare Drug Coding Drops Six-Month Marketing Requirement

Changes to the HCPCS coding process for Part B drugs are issued by the Centers for Medicare & Medicaid Services' Council on Technology & Innovation. The changes will be phased in over 18 months beginning with the 2006 coding cycle.

Related Content

Topics

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel